thalidomide has been researched along with Chronic Kidney Diseases in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The negative impact of inflammation in this CKD model was overcome by the marked anti-inflammatory effects of thalidomide, promoting renal protection." | 7.79 | Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice. ( Blanco, P; Catanozi, S; de Sá Lima, L; Degaspari, S; Dellê, H; Noronha, IL; Santana, AC; Scavone, C; Silva, C; Solez, K, 2013) |
| "Thalidomide was added to the BD therapy but was discontinued because of drug-induced eczema." | 5.43 | Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis. ( Hangaishi, A; Hirao, M; Iizuka, H; Kida, M; Usuki, K, 2016) |
| " The negative impact of inflammation in this CKD model was overcome by the marked anti-inflammatory effects of thalidomide, promoting renal protection." | 3.79 | Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice. ( Blanco, P; Catanozi, S; de Sá Lima, L; Degaspari, S; Dellê, H; Noronha, IL; Santana, AC; Scavone, C; Silva, C; Solez, K, 2013) |
| " The basis of the RI treatment in MM is bortizomib-based regimen, which does not require dosage adjustment in patients with dialysis or renal insufficiency." | 1.46 | [Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma]. ( , 2017) |
| "Thalidomide was added to the BD therapy but was discontinued because of drug-induced eczema." | 1.43 | Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis. ( Hangaishi, A; Hirao, M; Iizuka, H; Kida, M; Usuki, K, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tokuyama, M | 1 |
| Shimizu, T | 1 |
| Yamada, T | 1 |
| Kondoh, A | 1 |
| Mabuchi, T | 1 |
| Mettang, T | 1 |
| Kremer, AE | 1 |
| Kida, M | 1 |
| Hirao, M | 1 |
| Iizuka, H | 1 |
| Hangaishi, A | 1 |
| Usuki, K | 1 |
| Santana, AC | 1 |
| Degaspari, S | 1 |
| Catanozi, S | 1 |
| Dellê, H | 1 |
| de Sá Lima, L | 1 |
| Silva, C | 1 |
| Blanco, P | 1 |
| Solez, K | 1 |
| Scavone, C | 1 |
| Noronha, IL | 1 |
1 review available for thalidomide and Chronic Kidney Diseases
| Article | Year |
|---|---|
Uremic pruritus.
Topics: Acupuncture Therapy; Amines; Anti-Inflammatory Agents; Calcium Channel Blockers; Cyclohexanecarboxyl | 2015 |
4 other studies available for thalidomide and Chronic Kidney Diseases
| Article | Year |
|---|---|
[Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
Topics: Consensus; Creatinine; Dexamethasone; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chain | 2017 |
Case of psoriasis vulgaris with atrial fibrillation, heart failure and chronic kidney disease which were found accidentally through blood examination during apremilast treatment.
Topics: Aged; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Creatinine; Electrocardiography; | 2019 |
Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis.
Topics: Aged; Angiogenesis Inhibitors; Humans; Male; Multiple Myeloma; Renal Dialysis; Renal Insufficiency, | 2016 |
Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice.
Topics: Adenine; Animals; Blotting, Western; Cytokines; Disease Models, Animal; Electrophoretic Mobility Shi | 2013 |